HOWARD W. ROBIN - 15 Aug 2022 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Signature
Mark A. Wilson
Issuer symbol
NKTR
Transactions as of
15 Aug 2022
Net transactions value
-$65,493
Form type
4
Filing time
17 Aug 2022, 19:39:18 UTC
Previous filing
17 May 2022
Next filing
18 Nov 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Award $0 +410,625 +66% $0.000000 1,031,566 15 Aug 2022 Direct F1
transaction NKTR Common Stock Sale $65,493 -13,759 -1.3% $4.76* 1,017,807 16 Aug 2022 Direct F2, F3
holding NKTR Common Stock 410 15 Aug 2022 by spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTR Common Stock Award $0 +821,250 $0.000000 821,250 15 Aug 2022 Common Stock 821,250 $4.91 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted in connection with a retention program and are in lieu of the Issuer's usual end-of-year annual performance grants. These RSUs vest over three years from the date of grant in substantially equal quarterly installments based on continued service.
F2 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3 This transaction was executed in multiple trades at prices ranging from $4.67 to $4.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer.
F4 Stock options were granted in connection with a retention program and are in lieu of the Issuer's usual end-of-year annual performance grants.
F5 Stock options vest over three years from the date of grant in substantially equal monthly installments based on continued service.